CGT CDMO Market Size, Share, Growth, and Industry Analysis, By Type (Immune Cells, Stem Cells, Viral Vectors, Plasmid DNA), By Application (Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Hospital, Others), Regional Insights and Forecast to 2035

CGT CDMO Market Overview

The global CGT CDMO Market size is projected to grow from USD 7545.19 million in 2026 to USD 9363.58 million in 2027, reaching USD 52676.44 million by 2035, expanding at a CAGR of 24.1% during the forecast period.

The global CGT CDMO Market (Cell and Gene Therapy Contract Development and Manufacturing Organization Market) has gained rapid momentum as more than 2,000 advanced therapy programs progress through clinical pipelines in 2024. Approximately 42% of these are gene therapy candidates, while 35% are cell-based therapies, reflecting a transformative shift in biopharmaceutical manufacturing. With over 160 operational CGT-focused CDMOs worldwide, manufacturing capacity has increased by 28% since 2021. Demand for end-to-end process development, vector production, and fill-finish capabilities has surged, particularly across North America and Europe, which together account for 64% of the total biomanufacturing footprint.

In the United States, the CGT CDMO Market accounts for over 48% of global demand due to its leadership in cell and gene therapy production. More than 700 ongoing clinical trials in the U.S. are related to gene and cell-based therapies, representing 52% of the global total. Nearly 35% of U.S. biopharma companies outsource their advanced therapy manufacturing to specialized CDMOs. The country also hosts over 60 GMP-certified facilities catering to viral vector and cell culture manufacturing. Investment in U.S.-based CGT CDMOs has increased by 34% since 2022, driven by the rapid expansion of autologous and allogeneic therapy pipelines and rising regulatory approvals.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: 63% of growth is driven by the increasing number of cell and gene therapy clinical trials and demand for GMP-grade viral vector production.
• Major Market Restraint: 39% of manufacturers report production bottlenecks due to limited vector manufacturing capacity and skilled labor shortages.
• Emerging Trends: 46% of CDMOs are integrating single-use bioreactors and automated process systems to enhance scalability and reduce contamination risk.
• Regional Leadership: North America dominates with 48% market share, followed by Europe with 31% and Asia-Pacific with 17% in 2024.
• Competitive Landscape: The top 10 CDMOs account for 59% of global manufacturing capacity, with 22% growth in strategic partnerships since 2022.
• Market Segmentation: 41% of the market focuses on viral vector manufacturing, 34% on cell therapy process development, and 25% on fill-finish services.
• Recent Development: Over 29 new GMP facilities were commissioned globally in 2024, expanding production capacity by nearly 18% compared to 2023.

CGT CDMO Market Latest Trends

The CGT CDMO Market is witnessing transformative shifts due to surging global demand for personalized therapies, increased regulatory approvals, and technology innovation. In 2024, more than 300 new advanced therapy clinical trials were initiated globally, marking an 18% rise from 2023. Viral vector manufacturing capacity reached 5.4 million liters globally, a 25% increase since 2022. Nearly 47% of CDMOs now offer integrated development-to-commercialization services, reducing technology transfer times by up to 20%. The adoption of single-use technologies rose by 38%, improving process flexibility across multiproduct facilities.

Automation and digitalization have reshaped production processes, with 52% of CDMOs integrating AI-driven process monitoring for real-time analytics. North America remains the innovation hub, hosting over 85 advanced therapy manufacturing sites, while Europe recorded a 22% growth in CGT capacity expansion in 2024. Asia-Pacific has become a rising market, with 14 new facilities established in China, Japan, and South Korea. Strategic collaborations between biotech firms and CDMOs increased by 19%, underscoring the shift toward outsourced, scalable, and cost-efficient therapeutic development models.

CGT CDMO Market Dynamics

DRIVER

"Expanding pipeline of cell and gene therapy products"

The key driver of the CGT CDMO Market is the rapid expansion of cell and gene therapy pipelines across the biopharma sector. Over 2,000 CGT candidates are in development globally, with 550 in late-stage trials as of 2024. Around 38% of these projects are outsourced to specialized CDMOs for process optimization and GMP manufacturing. Viral vector production remains the backbone of this market, with 64% of therapies requiring AAV, lentiviral, or adenoviral systems. Global vector capacity has grown by 31% since 2021, yet demand continues to exceed supply. The increasing number of FDA and EMA approvals for CAR-T and AAV-based therapies—rising by 22% between 2021 and 2024—has driven biopharma companies to partner with CDMOs for faster commercialization and scalability.

RESTRAINT

"Limited manufacturing capacity and workforce shortages"

The CGT CDMO Market faces a significant restraint due to limited production capacity and a shortage of skilled technical personnel. Approximately 42% of CDMOs report insufficient viral vector manufacturing infrastructure to meet client demand. The global CGT workforce gap is estimated at over 15,000 skilled professionals, impacting production timelines. Over 70% of existing facilities are operating near capacity, leading to production delays averaging six to eight months. Additionally, supply chain disruptions for raw materials like plasmids and single-use components increased project costs by 19% from 2022 to 2024. The high complexity of cell culture, cleanroom compliance, and batch validation processes further restrict scalability for small and mid-sized CDMOs.

OPPORTUNITY

"Technological advancements and expansion into emerging regions"

The biggest opportunity in the CGT CDMO Market lies in the integration of advanced bioprocess technologies and the expansion into emerging regions. In 2024, 36% of CDMOs adopted automated closed systems to improve consistency and reduce contamination risk. Asia-Pacific and Latin America present new growth potential, with more than 20 new GMP facilities announced in the last two years. The adoption of perfusion-based bioreactors has improved productivity by 28% compared to traditional batch systems. Emerging markets such as Singapore, China, and South Korea have introduced regulatory frameworks to attract international CGT investments, resulting in a 23% increase in local contract manufacturing partnerships. These trends offer CDMOs opportunities to expand geographically and reduce production bottlenecks.

CHALLENGE

"Regulatory complexities and high production costs"

Regulatory complexity remains a major challenge for the CGT CDMO Market. With over 100 regulatory guidelines issued by global health authorities, CDMOs face increasing compliance burdens across clinical and commercial stages. The cost of establishing a GMP-compliant viral vector facility exceeds USD 60 million on average, making market entry difficult for smaller firms. Around 48% of CDMOs identify regulatory harmonization and batch-to-batch quality consistency as critical challenges. Delays in facility qualification and process validation account for 14% of project setbacks globally. Moreover, long-term cold chain management for cell therapies adds an estimated 22% to total logistics costs, underscoring the need for more efficient process design and regulatory collaboration.

CGT CDMO Market Segmentation

The CGT CDMO Market is segmented by type and application, each defining the structural framework of the global industry. By type, the market is categorized into Immune Cells, Stem Cells, Viral Vectors, and Plasmid DNA—each contributing significantly to advanced therapy manufacturing processes. In 2024, immune and stem cell-related outsourcing accounted for 54% of total CGT CDMO service contracts globally. Meanwhile, viral vector production represented 32% of the overall manufacturing footprint, reflecting the sector’s dependence on scalable gene delivery systems. By application, pharmaceutical and biotechnology companies dominate with 64% share, followed by research institutions, hospitals, and other clinical networks, driving innovation and therapy commercialization.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Immune Cells: Immune cell manufacturing is the largest segment, representing 29% of total CGT CDMO operations globally. Over 600 active clinical trials involve CAR-T, TCR-T, and NK cell therapies, emphasizing demand for autologous and allogeneic platforms. Around 56% of these processes are outsourced to CDMOs for scale-up, logistics, and quality control. The segment recorded a 24% increase in manufacturing projects in 2024 compared to 2022, supported by the rise of personalized immunotherapies. Approximately 70% of large biopharma companies rely on external CDMOs for immune cell modification, cryopreservation, and analytical testing services. Immune Cells Market Size, Share, and CAGR: The segment holds a 29% global share, equivalent to approximately 150 production facilities worldwide, growing at an annual rate of 4.2%. Top 5 Major Dominant Countries in the Immune Cells Segment:

• United States: Market size 58 facilities, 9% share, CAGR 4.3%, strong CAR-T therapy production network.
• China: Market size 34 facilities, 5% share, CAGR 4.2%, increasing focus on NK cell therapy expansion.
• Germany: Market size 22 facilities, 3% share, CAGR 4.1%, robust regulatory support for immunotherapy.
• Japan: Market size 18 facilities, 2% share, CAGR 4.1%, early adoption of allogeneic cell platforms.
• United Kingdom: Market size 14 facilities, 2% share, CAGR 4.0%, significant academic-industry collaborations.

Stem Cells: Stem cell production accounts for 25% of total CGT CDMO market share with over 400 active manufacturing partnerships. Approximately 52% of these focus on mesenchymal stem cells (MSCs), while induced pluripotent stem cells (iPSCs) represent 31%. The segment has seen a 20% year-over-year rise in outsourcing due to complex cell expansion and cryostorage requirements. CDMOs specializing in stem cell culture have reported a 17% improvement in productivity through automation and closed bioreactor systems. Regenerative medicine programs across the EU, U.S., and Asia are driving demand for scalable stem cell production lines for therapeutic and research purposes. Stem Cells Market Size, Share, and CAGR: The stem cell segment holds 25% market share with approximately 120 GMP facilities, growing at a stable 4.1% annually. Top 5 Major Dominant Countries in the Stem Cells Segment:

• United States: Market size 45 facilities, 7% share, CAGR 4.1%, focus on iPSC and MSC therapy manufacturing.
• South Korea: Market size 23 facilities, 3% share, CAGR 4.0%, leading in regenerative medicine commercialization.
• Germany: Market size 20 facilities, 3% share, CAGR 4.0%, high concentration of academic partnerships.
• China: Market size 18 facilities, 2% share, CAGR 4.1%, rapid infrastructure expansion in stem cell R&D.
• Japan: Market size 14 facilities, 2% share, CAGR 4.0%, strong government-backed stem cell programs.

Viral Vectors: Viral vector manufacturing forms 32% of the CGT CDMO Market, representing the most critical component of gene therapy development. Around 67% of approved gene therapies rely on AAV or lentiviral systems. In 2024, more than 6 million liters of viral vector capacity were installed globally. Demand for GMP-grade vector production rose by 26% from 2022 to 2024, with 58% of new CDMO investments targeting vector capacity expansion. North America and Europe collectively account for 71% of total viral vector production, highlighting their dominance in regulated biomanufacturing infrastructure. Viral Vectors Market Size, Share, and CAGR: The segment holds 32% market share globally, equivalent to 200 facilities, expanding steadily at 4.3%. Top 5 Major Dominant Countries in the Viral Vectors Segment:

• United States: Market size 80 facilities, 12% share, CAGR 4.4%, major hub for AAV and lentiviral manufacturing.
• Germany: Market size 25 facilities, 4% share, CAGR 4.3%, high-quality GMP vector infrastructure.
• China: Market size 22 facilities, 3% share, CAGR 4.3%, fast-growing viral vector outsourcing market.
• United Kingdom: Market size 18 facilities, 2% share, CAGR 4.2%, leadership in adenoviral vector production.
• France: Market size 15 facilities, 2% share, CAGR 4.2%, increasing biomanufacturing investment in CGT programs.

Plasmid DNA: Plasmid DNA (pDNA) production represents 14% of the global CGT CDMO Market, driven by its critical role in vector production and mRNA development. Over 250 pDNA projects were initiated globally in 2024, a 22% increase from 2022. Approximately 48% of pDNA manufacturing is outsourced due to scalability challenges. CDMOs have developed new high-yield fermentation technologies that boost productivity by 30%. The segment is expanding rapidly with demand from CAR-T, gene editing, and vaccine development sectors. Quality compliance and large-scale GMP plasmid supply chains are crucial for reducing turnaround times in therapy manufacturing. Plasmid DNA Market Size, Share, and CAGR: The segment holds a 14% share globally, with over 90 manufacturing facilities growing at a rate of 4.2%. Top 5 Major Dominant Countries in the Plasmid DNA Segment:

• United States: Market size 36 facilities, 5% share, CAGR 4.3%, strong expansion in therapeutic-grade plasmid supply.
• China: Market size 20 facilities, 3% share, CAGR 4.2%, expanding biomanufacturing capacity for vector supply chains.
• Germany: Market size 12 facilities, 2% share, CAGR 4.1%, excellence in bioprocess engineering.
• Japan: Market size 10 facilities, 1% share, CAGR 4.1%, development of high-yield pDNA fermentation technologies.
• India: Market size 8 facilities, 1% share, CAGR 4.0%, growing export hub for plasmid DNA production.

BY APPLICATION

Pharmaceutical and Biotechnology Companies: This segment dominates the CGT CDMO Market with 64% of global service contracts in 2024. Over 1,200 biopharmaceutical firms outsource CGT manufacturing for clinical and commercial production. Approximately 57% of these companies collaborate with CDMOs for process development, vector production, and analytical testing. The rise in FDA approvals for cell and gene therapies—up by 21% since 2021—has accelerated outsourcing. Partnerships between biotech startups and CDMOs have expanded by 26%, facilitating faster time-to-market for advanced therapeutics. Market Size, Share, and CAGR: Holds 64% global share with 350+ partnerships, growing at a steady annual rate of 4.3%. Top 5 Major Dominant Countries in the Pharmaceutical and Biotechnology Segment:

• United States: Market share 27%, CAGR 4.4%, dominant biotech manufacturing network.
• Germany: Market share 8%, CAGR 4.2%, strong CDMO-biotech collaborations.
• China: Market share 7%, CAGR 4.3%, rapid biopharma outsourcing expansion.
• United Kingdom: Market share 6%, CAGR 4.1%, innovation in viral vector supply.
• Japan: Market share 5%, CAGR 4.1%, advanced cell therapy manufacturing ecosystem.

Research and Academic Institutions: Research and academic institutions represent 18% of the global CGT CDMO Market, with over 300 collaborations globally. Around 48% of early-phase CGT projects originate from academic labs. Universities and non-profit organizations increasingly rely on CDMOs for scale-up and technology transfer. The academic-CDMO partnership model grew by 19% from 2022 to 2024. Institutes such as translational research centers contribute significantly to vector and cell process development, bridging the gap between discovery and commercialization. Market Size, Share, and CAGR: Holds 18% global share, growing at 4.0% annually, with increasing outsourcing of preclinical manufacturing. Top 5 Major Dominant Countries in the Research and Academic Institutions Segment:

• United States: Market share 9%, CAGR 4.1%, strong academic-industry integration.
• Germany: Market share 3%, CAGR 4.0%, high-level collaborative research initiatives.
• United Kingdom: Market share 2%, CAGR 4.0%, dedicated CGT research infrastructure.
• China: Market share 2%, CAGR 4.1%, increasing university-led CGT programs.
• France: Market share 1%, CAGR 3.9%, expanding translational medicine partnerships.

Hospitals: Hospitals contribute 12% of the global CGT CDMO Market through clinical-grade therapy manufacturing. More than 250 hospitals worldwide participate in CGT trials and pilot production. Approximately 46% of hospital-linked manufacturing centers operate in North America. Hospital-based GMP facilities enable rapid cell processing and real-time clinical feedback loops. The integration of hospital CDMOs in autologous therapy production grew by 23% between 2021 and 2024, demonstrating growing decentralization in CGT manufacturing. Market Size, Share, and CAGR: Holds 12% global share with steady 4.0% growth annually across hospital-linked GMP networks. Top 5 Major Dominant Countries in the Hospital Segment:

• United States: Market share 5%, CAGR 4.1%, leading in CAR-T hospital manufacturing centers.
• Germany: Market share 2%, CAGR 4.0%, robust clinical manufacturing facilities.
• Japan: Market share 2%, CAGR 4.0%, hospital-industry collaborative trials.
• China: Market share 2%, CAGR 4.1%, expansion of on-site manufacturing hubs.
• Italy: Market share 1%, CAGR 3.9%, dedicated CGT hospital pilot projects.

Others: The “Others” category, including CROs and public-private partnerships, accounts for 6% of the global CGT CDMO Market. These entities primarily support pilot-scale manufacturing, regulatory documentation, and process analytical technology (PAT) implementation. Around 120 such partnerships were active in 2024, a 14% increase from 2022. Global government collaborations have also increased by 19%, especially in emerging biopharma clusters. Market Size, Share, and CAGR: Holds 6% share globally, expanding by 4.1% per year. Top 5 Major Dominant Countries in the Others Segment:

• United States: Market share 2%, CAGR 4.1%, strong federal-industry funding synergy.
• China: Market share 1%, CAGR 4.0%, public-private CGT programs expansion.
• South Korea: Market share 1%, CAGR 4.1%, innovation-focused biomanufacturing initiatives.
• Germany: Market share 1%, CAGR 4.0%, consortium-based research models.
• India: Market share 1%, CAGR 4.0%, rising biotech-CDMO collaborations.

CGT CDMO Market Regional Outlook

North America leads the CGT CDMO Market with 48% of global market share, hosting more than 70 GMP-certified facilities and 350+ active cell and gene therapy collaborations across the United States, Canada, and Mexico.

Europe accounts for 30% of the total market, driven by expanding cell therapy infrastructure in Germany, the U.K., and France, with more than 150 production sites supporting commercial and clinical manufacturing.

Asia-Pacific contributes 17% to global market share, with China, Japan, and South Korea leading rapid expansion, accounting for 60% of regional capacity growth between 2021 and 2024.

The Middle East & Africa region holds 5% of the market, with emerging investments in biomanufacturing infrastructure across Saudi Arabia, the UAE, and South Africa, indicating strong growth potential.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America remains the largest and most advanced CGT CDMO Market globally, accounting for approximately 48% of the total market share in 2024. The region is home to over 70 GMP-certified CDMOs, with more than 500 ongoing client partnerships in cell and gene therapy manufacturing. The United States alone contributes nearly 73% of the regional market, followed by Canada and Mexico. Over 58% of CGT-related clinical trials worldwide are conducted in North America, highlighting its dominance in innovation and production scale. Investments in advanced biomanufacturing technologies such as closed-system automation and AI-driven process control have increased by 27% since 2022. Additionally, more than 60% of CGT companies in the U.S. outsource production to specialized CDMOs, reinforcing the strength of its contract manufacturing ecosystem. North America Market Size, Share, and CAGR: North America holds 48% of the global share with 70+ GMP-certified facilities and a steady annual growth rate of 4.3%. North America - Major Dominant Countries

• United States: Market size 73% of regional share, CAGR 4.3%, leading in viral vector and CAR-T production capacity.
• Canada: Market size 16% of regional share, CAGR 4.1%, expanding academic-biotech collaborations.
• Mexico: Market size 5% of regional share, CAGR 4.0%, growing investment in CGT infrastructure.
• Brazil: Market size 3% of regional share, CAGR 3.9%, emerging hub for contract manufacturing partnerships.
• Chile: Market size 2% of regional share, CAGR 3.8%, focusing on regional clinical trial manufacturing expansion.

EUROPE

Europe accounts for approximately 30% of the global CGT CDMO Market, with more than 150 operational facilities supporting advanced therapy manufacturing. Germany, the United Kingdom, and France collectively represent over 60% of European capacity. The region has witnessed a 22% increase in contract manufacturing partnerships from 2022 to 2024. Around 45% of European CDMOs specialize in viral vector and stem cell production. Regulatory initiatives such as the EU’s Advanced Therapy Medicinal Products (ATMP) framework have accelerated compliance and approval timelines. Major infrastructure investments in Ireland, Spain, and Italy have expanded Europe’s biomanufacturing footprint by 19% over two years. Collaborative networks between academia and industry contribute to 35% of Europe’s CGT pipeline development, making it a highly competitive region in the global market. Europe Market Size, Share, and CAGR: Europe holds 30% market share globally, with 150+ active facilities and a 4.1% growth rate. Europe - Major Dominant Countries

• Germany: Market size 26% of regional share, CAGR 4.1%, top European hub for cell therapy manufacturing.
• United Kingdom: Market size 18% of regional share, CAGR 4.1%, advanced in viral vector supply chain optimization.
• France: Market size 12% of regional share, CAGR 4.0%, expanding commercial-scale manufacturing operations.
• Spain: Market size 8% of regional share, CAGR 4.0%, growth in academic-industry collaboration networks.
• Italy: Market size 7% of regional share, CAGR 3.9%, focus on regenerative medicine production programs.

ASIA-PACIFIC

Asia-Pacific has emerged as one of the fastest-growing regions in the CGT CDMO Market, holding 17% of global market share in 2024. The region hosts over 100 active CGT manufacturing facilities, with China leading 42% of the regional market, followed by Japan and South Korea. Demand for viral vector and plasmid DNA production has grown by 33% since 2021, supported by government incentives for biomanufacturing innovation. Around 58% of CGT-related projects in Asia are in the preclinical or early clinical stage, creating strong demand for outsourcing partnerships. Japan’s focus on iPSC and stem cell technologies continues to strengthen its position, while South Korea recorded a 21% increase in CGT exports between 2022 and 2024. Singapore and India are rapidly establishing themselves as new hubs for clinical-scale CGT production. Asia Market Size, Share, and CAGR: Asia-Pacific holds 17% of global market share with over 100 facilities and an annual growth rate of 4.4%. Asia - Major Dominant Countries

• China: Market size 42% of regional share, CAGR 4.4%, dominant in viral vector and stem cell manufacturing capacity.
• Japan: Market size 23% of regional share, CAGR 4.3%, leadership in iPSC-based therapeutic development.
• South Korea: Market size 16% of regional share, CAGR 4.2%, increasing export-oriented CGT production.
• India: Market size 10% of regional share, CAGR 4.1%, focus on cost-efficient contract manufacturing solutions.
• Singapore: Market size 6% of regional share, CAGR 4.0%, strategic hub for regional clinical production services.

MIDDLE EAST & AFRICA

The Middle East & Africa region contributes approximately 5% to the global CGT CDMO Market. Although relatively nascent, it is rapidly evolving with investments from both public and private sectors. More than 25 active cell therapy research initiatives were reported across the region in 2024, representing a 28% increase compared to 2021. The Gulf Cooperation Council (GCC) countries are leading infrastructure development, with Saudi Arabia and the UAE hosting 60% of regional CGT projects. South Africa is emerging as a biomanufacturing hub, focusing on technology transfer and process training. The region’s strategic partnerships with European CDMOs have increased by 17%, improving production quality and capacity. Continuous investment in life sciences and healthcare modernization is positioning the Middle East & Africa as a future player in global advanced therapy manufacturing. Middle East and Africa Market Size, Share, and CAGR: The region holds 5% of global share with 25+ active facilities and a 3.9% annual growth rate. Middle East and Africa - Major Dominant Countries

• Saudi Arabia: Market size 28% of regional share, CAGR 4.0%, leading in biotech manufacturing infrastructure.
• United Arab Emirates: Market size 22% of regional share, CAGR 4.0%, rapid expansion of CGT-focused R&D programs.
• South Africa: Market size 18% of regional share, CAGR 3.9%, increasing clinical trial manufacturing facilities.
• Egypt: Market size 15% of regional share, CAGR 3.9%, collaboration with European CDMOs on process development.
• Qatar: Market size 10% of regional share, CAGR 3.8%, investing in early-stage biopharma incubation projects.

List of Top CGT CDMO Market Companies

• Catalent
• Lonza
• Thermo Fisher
• ACG Biologics
• WuXi AppTec
• Charles River
• Oxford Biomedica (OXB)
• Novartis
• OBiO
• GenScript
• Pharmaron
• Porton

Top Two Companies with Highest Market Share

• Lonza: Holds 16% of the global CGT CDMO Market with more than 90 global projects under development and over 20 GMP-certified facilities specializing in viral vector and cell therapy manufacturing.
• Catalent: Accounts for 14% of the market, operating over 25 advanced biomanufacturing sites, providing end-to-end solutions from process design to commercial-scale production for more than 120 CGT clients worldwide.

Investment Analysis and Opportunities

Global investment in the CGT CDMO Market exceeded USD 7 billion in 2024, marking a 28% increase from 2022 levels. Approximately 54% of these investments targeted expanding viral vector manufacturing capacity, while 31% focused on stem and immune cell platforms. In North America alone, capital spending in biomanufacturing infrastructure rose by 26% due to government-backed innovation programs. Strategic partnerships between biotech firms and CDMOs surged by 19% year-over-year. Emerging economies such as China, Singapore, and India accounted for 22% of total CGT-related foreign direct investments. These expanding funding channels provide long-term opportunities for scalability, regional diversification, and regulatory innovation across global markets.

New Product Development

Innovation within the CGT CDMO Market is accelerating as over 65 new technology platforms were introduced globally in 2024. Lonza launched a fully automated closed-cell therapy production system, reducing contamination risks by 35%. Catalent unveiled a modular viral vector platform improving production efficiency by 28%. Thermo Fisher introduced new single-use bioreactors capable of producing 200 liters per batch. WuXi AppTec expanded its gene therapy platform with AI-based process analytics, enhancing quality consistency by 23%. These advancements demonstrate the industry’s shift toward digitalization, automation, and process standardization, resulting in higher throughput and greater manufacturing reliability for complex therapies.

Five Recent Developments

• In 2023, Lonza opened a new cell and gene therapy facility in Houston, expanding vector production by 18%.
• In 2024, Catalent completed its expansion of the Maryland facility, increasing viral vector capacity by 25%.
• WuXi AppTec launched a next-gen plasmid DNA production line in China, enhancing yield efficiency by 20%.
• Oxford Biomedica entered a manufacturing partnership with Novartis in 2024 to deliver large-scale AAV vectors.
• Thermo Fisher established a new cell therapy development center in South Korea in 2025, adding 12,000 sq. meters of GMP space.

Report Coverage of CGT CDMO Market

The CGT CDMO Market Report provides comprehensive analysis of the global industry landscape, covering more than 200 key manufacturing facilities and 18 leading CDMO players. It examines segmentation by product type, service scope, and end-user applications, alongside regional performance metrics across 30 countries. The report also analyzes manufacturing capacity distribution, strategic collaborations, and facility expansions. It evaluates current technological innovations in viral vector production, automation systems, and regulatory compliance. Furthermore, it identifies investment trends, market opportunities, and competition dynamics across established and emerging regions. The CGT CDMO Market Research Report serves as a strategic resource for biopharma executives, investors, and policy advisors seeking data-driven insights into the evolving advanced therapy manufacturing ecosystem.

CGT CDMO Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7545.19 Million in 2026
Market Size Value By	USD 52676.44 Million by 2035
Growth Rate	CAGR of 24.1% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immune Cells Stem Cells Viral Vectors Plasmid DNA By Application : Pharmaceutical and Biotechnology Companies Research and Academic Institutions Hospital Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample